Clinical and epidemiological characterization of patients with lupus nephropathy in Santander, Colombia: the importance of the renal biopsy
PDF (Español)
HTML (Español)
PDF

Keywords

Colombia, Lupus Erythematosus Systemic, Lupus Nephropathy,Biopsy, proteinuria, chronic kidney insuficency.

How to Cite

1.
Torres - Bustamante M, Palomino - Suárez D, Celis AM, Nuñez SF, Hernández - Sierra AP. Clinical and epidemiological characterization of patients with lupus nephropathy in Santander, Colombia: the importance of the renal biopsy. Rev. Colomb. Nefrol. [Internet]. 2019 Sep. 11 [cited 2024 Jul. 15];6(2):122-9. Available from: https://revistanefrologia.org/index.php/rcn/article/view/370

Abstract

Introduction: Systemic Lupus Erythematosus (SLE) has different clinical manifestations, being very relevant lupus nephropathy (NL) because is associated with progression to advanced chronic kidney disease (CKD) and mortality.

Objective: Determination of the clinical and epidemiological characteristics of the NL in Santander.

Methods: A descriptive observational study of a series of cases in patients with NL diagnosis, evaluated between January 2017 and 2018 for the first time in a nephroprotection consultation. Qualitative and quantitative variables are defined according to the inclusion and exclusion criteria. Electronic medical records were reviewed, and data analysis was performed through SPSS®.

Results: 14 patients (85% women) were studied. The average age of diagnosis of NL was 36 years, mostly with stages of CKD 1 and 2 (72%) with proteinuria A3 (85%).Biopsy renal was performed in the 64%, a conclusive result in the 50%, being the histopathological grade IV of NL the most common. The most frequent maintenance therapy was corticosteroid alone (35.7%), followed by the combination of corticosteroid and mycophenolate (28.5%).

Conclusion: NL predominates in young women, and presenting in early stages of CKD, with high degrees of proteinuria, so a thorough evaluation should be performed in search of NL in all patients with SLE through early nephrological screening and monitoring programs. The histopathological grade IV found is like that reported in Latin America. There are administrative and technical difficulties in the perfomance of renal biopsies, emphasis should be placed on the realization of this procedure because it takes a primary role in defining the treatment.

https://doi.org/10.22265/acnef.6.2.370
PDF (Español)
HTML (Español)
PDF

References

Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper G. Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus. Semin Arthritis Rheum. 2010;39(4):1–23. http://dx.doi.org/10.1016/j.semarthrit.2008.10.007

Fernández-ávila DG, Rincón-riaño DN, Cock DR. Prevalencia y características demográficas del Lupus Eritematoso Sistémico en Colombia , según información del Sistema Integral de Información de la Protección Social. 2017;(August).

Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology [Internet]. 2016 Feb;55(2):252–62. Available from: https://academic.oup.com/ rheumatology/article-lookup/doi/10.1093/rheumatology/kev311

Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5): 825-835. http://dx.doi.org/10.2215/ CJN.05780616

Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients with Systemic Lupus Erythematosus: Ethnic and Disease Heterogeneity among “Hispanics.” Medicine (Baltimore). 2004;83(1):1–17. http://dx.doi.org/10.1097/01.md.0000104742.42401.e2

Pinto peñaranda LF. Nefropatía lúpica. Rev. Colomb. Nefrol. 2014;1(2):104-17.

Anaya JM, Cañas C, Mantilla RD, Pineda-Tamayo R, Tobón GJ, Herrera-Diaz C, et al. Lupus nephritis in colombians: Contrasts and comparisons with other populations. Clin Rev Allergy Immunol. 2011;40(3):199–207. http://dx.doi.org/10.1007/s12016-010-8249-4

Anaya JM, Uribe M, Pérez A, Sánchez JF, Pinto LF, Molina JF, et al. Clinical and immunological factors associated with lupus nephritis in patients from northwestern Colombia. Biomedica. 2003;23(3):293–300.

Arroyo A, García R, Aroca G, Acosta J. Correlación clínica e inmunohistopatológica de la nefropatía lúpica en un centro de referencia del Caribe colombiano durante los años 2012 a 2013. Rev Colomb Nefrol. 2014;1(2):57–64.

https://doi.org/10.22265/acnef.1.2.176

Aroca G. Modelo de gestión de salud de la nefritis lúpica. 2017. 277 p.

Yokoyama H, Okuyama H. Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians. Clin Exp Nephrol. 2011;15(3):321–30. https://doi.org/10.1007/s10157-011-0434-0

Schwartz MM, Korbet SM, Lewis EJ, Study C. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transpl. 2008;23(4):1298–306. https://doi.org/10.1093/ndt/gfm775

Ruiz-irastorza G, Espinosa G, Frutos MA, Jiménez-alonso J, Praga M, Pallarés L, et al. Diagnóstico y tratamiento de la nefritis lúpica Documento. Rev Nefrol. 2012;32(suppl 1):1–35.

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–45. http://dx.doi.org/10.1136/annrheumdis-2019-215089

Kidney Disease Improving Global Outcomes. KDIGO Clinical practice guideline for glomerulonephritis. Kidnet Int Suppl [Internet]. 2012;2(2):1–274. Available from: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-GN-Guideline.pdf

Lightstone L, Doria A, Wilson H, Ward FL, Larosa M, Bargman JM. Can we manage lupus nephritis without chronic corticosteroids administration? Autoimmun Rev [Internet]. 2018;17(1):4–10. Available from: https://doi.org/10.1016/j.autrev.2017.11.002

Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology. Ann Rheum Dis. 2018;1-9.

Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology [Internet]. 2010 Jan [cited 2018 Sep 5];49(1):128–40. Available from:http:// www.ncbi.nlm.nih.gov/pubmed/19933596

Pons-Estel GJ, Alarcón GS, Hachuel L, Boggio G, Wojdyla D, Pascual-Ramos V, et al. Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology (Oxford) [Internet]. 2012 Jul [cited 2018 Sep 5];51(7):1293–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22389125

No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.

Dimensions


PlumX


Downloads

Download data is not yet available.